Chimeric Therapeutics Limited
CHMMF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | $7,130 | $5,554 | -$3,513 | $5,485 |
| % Growth | 28.4% | 258.1% | -164% | – |
| Cost of Goods Sold | $847 | $0 | -$483 | $487 |
| Gross Profit | $6,284 | $5,554 | -$3,513 | $10,970 |
| % Margin | 88.1% | 100% | 100% | 200% |
| R&D Expenses | $10,185 | $4,163 | $12,648 | $4,342 |
| G&A Expenses | $3,095 | $3,351 | $4,763 | $2,118 |
| SG&A Expenses | $3,480 | $4,052 | $4,128 | $4,384 |
| Sales & Mktg Exp. | $385 | $701 | -$63 | $2,266 |
| Other Operating Expenses | $115 | $0 | -$5,325 | $0 |
| Operating Expenses | $13,780 | $8,215 | $11,451 | $8,727 |
| Operating Income | -$7,496 | -$2,661 | -$16,776 | $2,654 |
| % Margin | -105.1% | -47.9% | 477.6% | 48.4% |
| Other Income/Exp. Net | -$104 | -$59 | -$6,829 | $0 |
| Pre-Tax Income | -$7,600 | -$2,720 | -$23,605 | -$3,471 |
| Tax Expense | $27 | $138 | -$8,631 | $73 |
| Net Income | -$7,573 | -$2,858 | -$14,974 | $2,444 |
| % Margin | -106.2% | -51.5% | 426.3% | 44.6% |
| EPS | -0.005 | -0.003 | -0.022 | 0.004 |
| % Growth | -60.7% | 87.3% | -600% | – |
| EPS Diluted | -0.005 | -0.003 | -0.022 | 0.004 |
| Weighted Avg Shares Out | 1,693,701 | 1,005,236 | 680,629 | 557,645 |
| Weighted Avg Shares Out Dil | 1,698,848 | 1,005,001 | 680,629 | 557,645 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $73 | $48 |
| Interest Expense | $104 | $59 | $0 | $332 |
| Depreciation & Amortization | $545 | $487 | $595 | $487 |
| EBITDA | -$3,282 | -$2,174 | -$13,468 | $2,244 |
| % Margin | -46% | -39.1% | 383.4% | 40.9% |